Skip to main content
SpringerLink
Log in

Gout treatment: What is evidence-based and how do we determine and promote optimized clinical care?

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Gout, a common form of inflammatory arthritis, has been markedly understudied relative to other rheumatologic conditions. As a result, evidence guiding clinical management in gout has traditionally been lacking. Burgeoning data suggests that quality of gout care in gout is frequently suboptimal. In this paper, we examine the evidence supporting gout management strategies in clinical practice. In addition, we examine consensus building efforts that have culminated in the recent publication of gout management quality indicators. We also discuss the need for future initiatives aimed at improving patient safety and quality of care in gout.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Mikuls T, MacLean C, Oliveri J, et al.: Quality of care indicators for gout management. Arthritis Rheum 2004, 50:937–943. Report summarizing the development of quality indicators for gout management.

    Article  PubMed  Google Scholar 

  2. Roberts C, Adebajo A, Long S: Improving the quality of care of musculoskeletal conditions in primary care. Rheumatol 2002, 41:503–508.

    Article  CAS  Google Scholar 

  3. Chin M, Wang L, Jin L, et al.: Appropriateness of medication selection for older persons in an urban academic emergency department. Acad Emerg Med 1999, 6:1232–1242.

    Article  PubMed  CAS  Google Scholar 

  4. Wallace S, Singer J, Duncan G, et al.: Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol 1991, 18:264–269.

    PubMed  CAS  Google Scholar 

  5. Wallace S, Singer J: Systemic toxicity associated with intravenous administration of colchicine - guidelines for use. J Rheumatol 1988, 15:495–499.

    PubMed  CAS  Google Scholar 

  6. Wallace S, Singer J: Review: systemic toxicity associated with the intravenous administration of colchicine -guidelines for use. J Rheumatol 1988, 15:495–499.

    PubMed  CAS  Google Scholar 

  7. Smith P, Karlson N, Nair B: Quality use of allopurinol in the elderly. J Qual Clin Pract 2000, 20:42–43.

    Article  PubMed  CAS  Google Scholar 

  8. Stamp L, Gow P, Sharples K, Raill B: The optimal use of allopurinol: an audit of allopurinol use in South Auckland. Aust N Z J Med 2000, 30:567–572.

    PubMed  CAS  Google Scholar 

  9. Hande K, Noone R, Stone W: Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984, 76:47–56.

    Article  PubMed  CAS  Google Scholar 

  10. Devlin J, Bellamy N, Bayliff C: Observations and effects of educational consults on allopurinol prescribing. Can J Hosp Pharm 1992, 45:21–27.

    PubMed  CAS  Google Scholar 

  11. Kennedy D, Hayney M, Lake K: Azathioprine and allopurinol: the price of an avoidable drug interaction. Ann Pharmacother 1996, 30:951–954.

    PubMed  CAS  Google Scholar 

  12. Venkat Raman G, Sharman V, Lee H: Azathioprine and allopurinol: a potentially dangerous combination. J Intern Med 1990, 228:69–71.

    Article  Google Scholar 

  13. Harris R, Helfand M, Woolf S, et al.: Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 2001, 20(Suppl):21–35.

    Article  PubMed  CAS  Google Scholar 

  14. Ahern M, Reid C, Gordon T, et al.: Does colchicine work? The results of the first controlled study in gout. Aus N Zealand J Med 1987, 17:301–304. The first ever randomized controlled trial examining the efficacy and tolerability of colchicine in the treatment of acute gout flares.

    CAS  Google Scholar 

  15. Davis J, Bartfeld H: The effect of intravenous colchicine on acute gout. Am J Med 1954, 16:218–219.

    Article  PubMed  Google Scholar 

  16. Davis J: Safety and effectiveness of colchicine by intravenous administration in the treatment of gout. J Clin Pharmacol 1969, 9:410–412.

    CAS  Google Scholar 

  17. Carmichael L: Treatment of acute gout with injection of colchicine. JAMA 1959, 170:1410–1411.

    CAS  Google Scholar 

  18. Mikuls T, Curtis J, Allison J, et al.: Medication errors with the use of gout related therapies: results from the United States Pharmacopeia MEDMARX surveillance system. Arthritis Rheum 2004, 50(Suppl):s812.

    Google Scholar 

  19. Calabro J, Khoury M, Smyth C: Clinoril in acute gout. Acta Rheum Port 1974, 8:163–166.

    Google Scholar 

  20. Emmerson B: Regimen of indomethacin therapy in acute gouty arthritis. BMJ 1967, 2:272–274.

    Article  PubMed  CAS  Google Scholar 

  21. Boardman P, Hart F: Indomethacin in the treatment of acute gout. Practitioner 1965, 194:560–565.

    PubMed  CAS  Google Scholar 

  22. Schweitz M, Nashel D, Alepa F: Ibuprofen in the treatment of acute gouty arthritis. JAMA 1978, 239:34–35.

    Article  PubMed  CAS  Google Scholar 

  23. Tausch G, Eberl R: Efficacy, tolerance and safety of piroxicam in the treatment of acute gout. Eur J Rheumatol Inflam 1978, 1:365–368.

    Google Scholar 

  24. Widmark P: Safety and efficacy of piroxicam in the treatment of acute gout. Eur J Rheumatol Inflam 1978, 1:346–348.

    Google Scholar 

  25. Murphy J: Piroxicam in the treatment of acute gout: a multicentre open study in general practice. J Intern Med Res 1979, 7:507–510.

    CAS  Google Scholar 

  26. Karachalios G: Treatment of gouty arthritis with piroxicam. Clin Exp Rheumatol 1985, 3:63–65.

    PubMed  CAS  Google Scholar 

  27. Karachalios G: Ibuprofen (brufen) treatment of acute gouty arthritis. Clin Trial J 1981, 18:176–179.

    Google Scholar 

  28. Kuzell W, Schaffarzick R, Brown B: Phenylbutazone (butazolidin) in rheumatoid arthritis and gout. JAMA 1952, 149:729–734.

    CAS  Google Scholar 

  29. Cuq P: Treatment of acute attacks of gout with naproxen. Scand J Rheumatol 1973, 2(Suppl 2):64–68.

    Article  Google Scholar 

  30. Marcolongo R, Lucchese M, Caruso I, et al.: IV indoprofen for prompt relief of acute gout. J Int Med Res 1980, 8:326–332.

    PubMed  CAS  Google Scholar 

  31. Fletcher M, Wade M: Clinical experience with isoxicam in patients with acute gout. Br J Clin Practice 1985, 39:108–113.

    CAS  Google Scholar 

  32. Willkens R, Case J, Huix F: The treatment of acute gout with naproxen. J Clin Pharm 1975, 15:363–366.

    CAS  Google Scholar 

  33. Wanasukapunt S, Lertratanakul Y, Rubinstein H: Effect of fenoprofen calcium on acute gouty arthritis. Arthritis Rheum 1976, 19:933–935.

    Article  PubMed  CAS  Google Scholar 

  34. Altman R, Honig S, Levin J, Lightfoot R: Ketoprofen vs. indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol 1988, 15:1422–1426.

    PubMed  CAS  Google Scholar 

  35. Eberl R, Dunky A: Meclofenamate sodium in the treatment of acute gout. Results of a double-blind study. Arzneimittel-Forschung 1993, 33:641–643.

    Google Scholar 

  36. Fraser R, Howard D, Walker F: Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricemia. J Royal Col Gen Pract 1987, 37:409–411.

    CAS  Google Scholar 

  37. Ruotsi A, Vainio U: Treatment of acute gouty arthritis with proquazone and indomethacin. A comparative, double-blind trial. Scand J Rheumatol 1978, 21(Suppl):15–17.

    Article  Google Scholar 

  38. Smyth C, Percy J: Comparison of indomethacin and phenylbutazone in acute gout. Practitioner 1973, 32:351–353.

    CAS  Google Scholar 

  39. Sturge R, Scott J, Hamilton E, et al.: Multicentre trial of naproxen and phenylbutazone in acute gout. Eur J Rheumatol Inflam 1979, 2:40–44.

    Google Scholar 

  40. Weiner G, White S, Weitzner R, Rubinstein H: Double-blind study of fenoprofen vs. phenylbutazone in acute gouty arthritis. Arthritis Rheum 1979, 22:425–426.

    Article  PubMed  CAS  Google Scholar 

  41. Reardon J, Stockman A, Darlington L, Scott J: Double-blind trial of feprazone and phenylbutazone in acute gout. Curr Med Res Opin 1980, 6:445–448.

    PubMed  CAS  Google Scholar 

  42. Butler R, Goddard D, Higgens C, et al.: Double-blind trial of fluriprofen and phenylbutazone in acute gouty arthritis. Br J Clin Pharmacol 1985, 20:511–513.

    PubMed  CAS  Google Scholar 

  43. Douglas G, Thompson M: Comparison of phenylbutazone and flufenamic acid in treatment of acute gout. Ann Phys Med 1970, 10:275–280.

    PubMed  CAS  Google Scholar 

  44. Tumrasvin T, Deesomchok U: Piroxicam in the treatment of acute gout. High dose versus low dose. J Med Ass Thailand 1985, 68:111–116.

    CAS  Google Scholar 

  45. Valdes E: Use of tenoxicam in patinets with acute gouty arthritis. Eur J Rheumatol Inflam 1987, 9:133–136.

    CAS  Google Scholar 

  46. Siegel L, Alloway J, Nashell D: Comparison of adrenocorticotropic hormone and triamcinolone in the treatment of acute gouty arthritis. J Rheumatol 1994, 21:1325–1327.

    PubMed  CAS  Google Scholar 

  47. Alloway J, Moriarty M, Hoogland Y, Nashel D: Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993, 20:111–113.

    PubMed  CAS  Google Scholar 

  48. Axelrod D, Preston S: Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988, 33:803–805.

    Article  Google Scholar 

  49. Groff G, Franck W, Raddatz D: Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Sem Arthritis Rheum 1990, 19:329–336.

    Article  CAS  Google Scholar 

  50. Brewis I, Ellis R, Scott J: Single daily dose of allopurinol. Ann Rheum Dis 1975, 34:256–259.

    Article  PubMed  CAS  Google Scholar 

  51. Rodnan G, Robin J, Tolchin S, Elion G: Allopurinol and gouty hyperuricemia. Efficacy of a single daily dose. JAMA 1975, 231:1143–1145.

    Article  PubMed  CAS  Google Scholar 

  52. Rundles R, Elion G, Hitchings G: Allopurinol in the treatment of gout secondary to hyperuricemia. Bull Rheum Dis 1966, 16:400–403.

    CAS  Google Scholar 

  53. Houpt J: Effect of allpurinol in the treatment of gout. Arthritis Rheum 1965, 8:899–904.

    Article  PubMed  CAS  Google Scholar 

  54. Klinenberg J, Goldfinger S, Seegmiller J: The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout. Ann Intern Med 1965, 62:639–647.

    PubMed  CAS  Google Scholar 

  55. Delbarre F, Amor B, Auscher C, de Gery A: Treatment of gout with allopurinol. A study of 106 cases. Ann Rheum Dis 1966, 25:627–633.

    PubMed  CAS  Google Scholar 

  56. Wymgaarden J, Rundles R, Silberman H, Hunter S: Control of hyperuricemia with hydroxypyrazolopyrimidine, a purine analogue which inhibits uric acid synthesis. Arthritis Rheum 1963, 6:306–307.

    Google Scholar 

  57. Yu T, Gutman A: Effect of allopurinol (4-hydroxypyrazole (3,4-d) pyrimidine) on serum and urinary uric acid in primary and secondary gout. Am J Med 1964, 37:639–647.

    Article  Google Scholar 

  58. Yu T: The effect of allopurinol in primary and secondary gout. Arthritis Rheum 1965, 8:905–906.

    Article  PubMed  CAS  Google Scholar 

  59. Wilson J, Simmonds H, North J: Allopurinol in the treatment of uraemic patients with gout. Ann Rheum Dis 1967, 26:136–142.

    Article  PubMed  CAS  Google Scholar 

  60. Smyth C: Studies of allopurinol in patients with tophaceous gout. Arthritis Rheum 1965, 8:907–910.

    Article  PubMed  CAS  Google Scholar 

  61. Hall A, Holloway V, Scott J: 4-hydroxypyazolo (3,4-d) pyrimidine (HPP) in the treatment of gout. Preliminary observations. Ann Rheum Dis 1964, 23:439–446.

    Article  PubMed  CAS  Google Scholar 

  62. McCarthy G, Barthelemy C, Veum J, Wortmann R: Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout. Arthritis Rheum 1991, 34:1489–1494.

    Article  PubMed  CAS  Google Scholar 

  63. Sorenson L, Levinson D: Clinical evaluation of benzbromarone. A new uricosuric drug. Arthritis Rheum 1976, 19:183–190.

    Article  Google Scholar 

  64. Persellin R, Schmid F: The use of sulfinpyrazone in the treatment of gout. Reduces uric acid level and deminishes severity of arthritic attacks with freedom from significant toxicity. JAMA 1961, 175:971–975.

    PubMed  CAS  Google Scholar 

  65. Bluestone R, Klinenberg J, Lee I: Benzbromarone as a longterm uricosuric agent. Adv Exp Med Bio 1980, 122A:283–286.

    CAS  Google Scholar 

  66. de Gery A, Auscher C, Saporta L, Delbarre F: Treatment of gout and hyperuricemia by benzbromarone ethyl 2 (dibromo-3,5 hydroxy-4 benzoyl)-3 benzofuran. Adv Exp Med Bio 1974, 41:683–689.

    Google Scholar 

  67. Yu T: Pharmacokinetic and clinical studies of a new uricosuric agent - benzbromarone. J Rheumatol 1976, 3:305–312.

    PubMed  CAS  Google Scholar 

  68. Talbott J, Bishop C, Norcross B, Lockie L: The clinical and metabolic effects of benemid in patients with gout. Trans Assoc Am Physicians 1951, 64:372–377.

    PubMed  CAS  Google Scholar 

  69. Ferber H, Bader U, Matzkies F: The action of benzbromarone in relation to age, sex, and accompanying diseases. Adv Exp Med Bio 1980, 122A:287–294.

    CAS  Google Scholar 

  70. Gaines L, Shulman L: The failure of uricosuric drugs to reduce the attack rate in primary non-tophaceous gout. Arthritis Rheum 1969, 12:663–664.

    Google Scholar 

  71. Gutman A, Yu T: Protracted uricosuric therapy in tophaceous gout. Lancet 1957, 2:1258–1260.

    Article  Google Scholar 

  72. Scott J: Comparison of allopurinol and probenecid. Ann Rheum Dis 1966, 25:623–626.

    PubMed  CAS  Google Scholar 

  73. Kuzell W, Seebach L, Glover R, Jackman A: Treatment of gout with allopurinol and sulphinpyrazone in combination and with allopurinol alone. Ann Rheum Dis 1966, 25:634–642.

    PubMed  CAS  Google Scholar 

  74. Perez-Ruiz F, Calabozo M, Pijoan J, et al.: Effect of uratelowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002, 47:356–360.

    Article  PubMed  CAS  Google Scholar 

  75. Wortmann R: Management of hyperuricemia. In Arthritis and Allied Conditions. 13th ed. Vol. 2. Edited by Koopman W. Baltimore: Williams & Wilkins; 1996:2073–2083.

    Google Scholar 

  76. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al.: Efficacy of allopurinol and benzbromarone for the control of hyperuricemia. A pathogenic approach to the treatment of chronic gout. Ann Rheum Dis 1998, 57:545–549.

    Article  PubMed  CAS  Google Scholar 

  77. Ferraz M, O’Brien B: A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol 1995, 22:908–914.

    PubMed  CAS  Google Scholar 

  78. Loebl W, Scott J: Withdrawal of allpurinol in patients with gout. Ann Rheum Dis 1974, 33:304–307.

    Article  PubMed  CAS  Google Scholar 

  79. Bull P, Scott J: Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol 1989, 16:1246–1248.

    PubMed  CAS  Google Scholar 

  80. vanLieshout-Zuidema M, Breedveld F: Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. J Rheumatol 1993, 20:1383–1385.

    PubMed  Google Scholar 

  81. Gast L: Withdrawal of longterm antihyperuricemic therapy in tophaceous gout. Clin Rheumatol 1987, 6:70–73.

    Article  PubMed  CAS  Google Scholar 

  82. Shoji A, Yamanaka H, Kamatani N: A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004, 51:321–325. Retrospective cohort study suggesting that the optimal target urate level for urate lowering therapy is = 6.0 mg/dL.

    Article  PubMed  CAS  Google Scholar 

  83. Li-Yu J, Clayburne G, Sieck M, et al.: Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001, 28:577–580.

    PubMed  CAS  Google Scholar 

  84. Grahame R, Scott J: Clinical study of 354 patients with gout. Ann Rheum Dis 1970, 29:461–468.

    Article  PubMed  CAS  Google Scholar 

  85. Wortmann R, Becker M, Schumacher HJ, et al.: Gout flare prophylaxis during management of chronic gout with febuxostat, a non-purine selective inhibitor of xanthine oxidase. Arthritis Rheum 2004, 50(Suppl):s801.

    Google Scholar 

  86. Hollingworth P, Reardon J, Scott J: Acute gout during hypuricaemic therapy: prophylaxis with colchicine. Ann Rheum Dis 1980, 39:529.

    Article  PubMed  CAS  Google Scholar 

  87. Paulus H, Schlosstein LH, Godfrey RG, et al.: Prophylactic colchicine treatment of intercritical gout. A placebocontrolled study of probenecid-treated patients. Arthritis Rheum 1974, 17:609–613.

    Article  PubMed  CAS  Google Scholar 

  88. Borstad G, Bryant L, Abel M, et al.: Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004, 31:2429–2432.

    PubMed  CAS  Google Scholar 

  89. Johnson R, Kang D, Feig D, et al.: Is there a pathogenic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension 2003, 41:1183–1190.

    Article  PubMed  CAS  Google Scholar 

  90. Kjeldsen S, Dahlof B, Devereux R, et al.: Efffects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002, 288:1491–1498.

    Article  PubMed  CAS  Google Scholar 

  91. Hoieggen A, Alderman M, Kjeldsen S, et al.: The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004, 65:1041–1049.

    Article  PubMed  CAS  Google Scholar 

  92. Kiefe C, Allison J, Williams O, Person et al.: Improving quality improvement using achievable benchmarks for physician feedback. JAMA 2001, 285:2871–2879.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Nebraska Medical Center and the Omaha VA Medical Center, 983025 NE Med Center, 68198-3025, Omaha, NE, USA

    Ted R. Mikuls MD, MSPH

Authors
  1. Ted R. Mikuls MD, MSPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth G. Saag MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mikuls, T.R., Saag, K.G. Gout treatment: What is evidence-based and how do we determine and promote optimized clinical care?. Curr Rheumatol Rep 7, 242–249 (2005). https://doi.org/10.1007/s11926-996-0046-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-996-0046-y

Keywords

Search

Navigation